Indium (In-111)klorid Curiumpharma

Indium-111 chloride, the active ingredient in Indium (In-111)klorid Curiumpharma, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed to visualize infection, inflammation, tumors and bone marrow activity in patients undergoing diagnostic imaging, and helps clinicians assess disease distribution and treatment response.

GNH USA supplies Indium (In-111)klorid Curiumpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide, with a focus on quality assurance and regulatory compliance. The company ensures traceability and adherence to EU pharmacopeial standards.

Indium-111 chloride is used in nuclear medicine to image infectious, inflammatory and neoplastic processes.

- Infection and inflammation imaging: enables visualization of infectious foci and inflammatory lesions, aiding diagnosis and treatment planning. - Tumor localization: highlights malignant tissue uptake, supporting tumor detection, staging and therapeutic monitoring. - Bone marrow imaging: delineates marrow activity, useful for assessing hematopoietic disorders and transplant engraftment.

Indium-111 chloride may be associated with the following adverse reactions, which are generally related to the radiopharmaceutical nature and the intravenous administration.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Flushing: temporary redness and warmth of the skin. - Headache: mild to moderate discomfort. - Warmth at injection site: brief sensation of heat. - Transient hypotension: short‑lasting drop in blood pressure. - Mild allergic reaction: rash or itching.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis: potentially life‑threatening. - Radiation‑induced tissue injury: damage to organs from radiation exposure. - Severe hypotension: prolonged low blood pressure. - Hemolysis: breakdown of red blood cells. - Bone marrow suppression: reduced blood cell production. - Nephrotoxicity: impairment of kidney function.

When using Indium-111 chloride, several safety considerations should be observed.

- Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal risk. - Breastfeeding: discontinue nursing or assess risk before administration. - Renal function: evaluate kidney performance as the agent is renally excreted. - Allergy: confirm no known hypersensitivity to indium compounds. - Radiation exposure: limit use to essential diagnostic procedures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 chloride can interact with other agents; awareness of major and moderate interactions helps ensure patient safety.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: additive radiation dose may exceed safety limits. - Chemotherapeutic agents affecting bone marrow: increased risk of marrow suppression. - High‑dose steroids: may alter biodistribution and imaging accuracy.

Moderate Interactions (Monitor Closely): - Iodinated contrast agents: may interfere with image interpretation. - Beta‑blockers: can mask hypotensive reactions. - Anticoagulants: may increase bleeding risk at the injection site.